Focus:
Comment
-
19 July 2019
Sage’s Zulresso for postpartum depression has uncertain payer coverage
Postpartum depression has a too-narrow definition and mothers who experience episodes after the defined window might find payers hesitant to cover the treatment.
-
18 July 2019
AZ’s Forxiga earns EU CHMP recommendation for inclusion of cardiovascular outcomes
Forxiga is indicated for monotherapy and combination therapy use to improve glycemic control with the additional benefits of weight loss and blood pressure reduction.
-
17 July 2019
Pregnancy outcomes in women with lupus significantly improved in the last 18 years
Systemic lupus erythematosus, commonly known as lupus (Latin for wolf), is a systemic autoimmune disease that predominantly affects women of childbearing age.
-
17 July 2019
Poor survival from diffuse large B-Cell lymphoma in older adults
It is worrying that so many patients with DLBCL were diagnosed in the advanced stages, as survival will be poor and patients would require aggressive therapy to get the cancer...
-
16 July 2019
Is the microbiome the key to success for immune checkpoint inhibitors?
Already three years ago researchers had shown that responding and non-responding patients have significant differences in the composition and diversity of their gut bacteria.
-
16 July 2019
Novartis’ acquisition of Xiidra will boost its short-term sales in ophthalmology
There remains a huge clinical unmet need for additional pharmacotherapies, particularly for a curative drug that can address the underlying cause of Dry Eye Syndrome.
-
16 July 2019
Severe haemophilia predominates globally
Haemophilia is a rare x-linked hereditary bleeding disorder that results in an inability of the blood to clot normally.
-
15 July 2019
Can JAK inhibitors penetrate the alopecia areata market effectively?
With the increase in JAK inhibitors being used off-label in AA, it is important to determine how this class of drugs will change the treatment landscape once approved by regulatory...
-
12 July 2019
Another failure in Alzheimer’s pipeline diminishes hopes for the BACE inhibitor class
Although umibecestat’s failure is disappointing, it is not surprising as most researchers now believe that BACE inhibitors fail because they stop amyloid formation too late in the course of the...
-
12 July 2019
Cannabis cream demonstrates myorelaxant effect with topical skin application in patients with TMD
Skeletal muscle relaxant cannabis cream study shows signs of success.